File size: 14,523 Bytes
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
 
06adf10
 
 
 
 
 
 
 
be415c5
 
06adf10
 
 
e0128c0
06adf10
be415c5
 
 
 
 
 
 
 
 
 
 
06adf10
 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
[
  {
    "id": "AITX-00001",
    "patient": {
      "genotype": [
        {
          "gene": "DMD",
          "transcript": "NM_004006.2",
          "variant_cdna": "c.7544_9286del",
          "variant_protein": "p.(Thr2516_Ala3096del)",
          "zygosity": "hemizygous"
        }
      ],
      "clinical_context": "Progressive muscle weakness"
    },
    "question": {
      "category": "Established_Targeted",
      "answer_format": "multiple_choice",
      "prompt": "To which of the following targeted therapies would this variant be most likely amenable: Golodirsen, Viltolarsen, Eteplirsen, Casimersen, Ataluren, or None?",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "Eteplirsen",
    "answer_explanation": "Variant results in deletion of exons 52-63, which is listed as amenable to exon 51 skipping",
    "difficulty_rationale": "",
    "sources": ["GeneReviews", "PubMed/Literature"],
    "citations": []
  },
  {
    "id": "AITX-00002",
    "patient": {
      "genotype": [
        {
          "gene": "DMD",
          "transcript": "NM_004006.2",
          "variant_cdna": "c.10453_10454delinsTA",
          "variant_protein": "p.(Leu3485Ter)",
          "zygosity": "hemizygous"
        }
      ],
      "clinical_context": "Progressive muscle weakness"
    },
    "question": {
      "category": "Established_Targeted",
      "answer_format": "multiple_choice",
      "prompt": "To which of the following targeted therapies would this variant be most likely amenable: Golodirsen, Viltolarsen, Eteplirsen, Casimersen, Ataluren, or None?",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "Ataluren",
    "answer_explanation": "Variant results in a nonsense in exon 74, which is amenable to nonsense readthrough",
    "difficulty_rationale": "",
    "sources": [],
    "citations": []
  },
  {
    "id": "AITX-00003",
    "patient": {
      "genotype": [
        {
          "gene": "DMD",
          "transcript": "NM_004006.2",
          "variant_cdna": "c.70T>C",
          "variant_protein": "p.(Trp24Arg)",
          "zygosity": "hemizygous"
        }
      ],
      "clinical_context": "Progressive muscle weakness"
    },
    "question": {
      "category": "Established_Targeted",
      "answer_format": "multiple_choice",
      "prompt": "To which of the following targeted therapies would this variant be most likely amenable: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Ataluren, or None?",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "None",
    "answer_explanation": "Results in a missense in exon 2, which is not amenable to nonsense readthrough and is upstream from skippable exons",
    "difficulty_rationale": "",
    "sources": [],
    "citations": []
  },
  {
    "id": "AITX-00004",
    "patient": {
      "genotype": [
        {
          "gene": "AGXT",
          "transcript": "NM_000030.3",
          "variant_cdna": "c.508G>A",
          "variant_protein": "p.(Gly170Arg)",
          "zygosity": "homozygous"
        }
      ],
      "clinical_context": "Recurrent nephrocalcinosis and chronic kidney disease"
    },
    "question": {
      "category": "Established_Targeted",
      "answer_format": "string_match",
      "prompt": "What targeted, small molecule therapy is available for this patient? Provide the generic name or None.",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "Pyridoxine",
    "answer_explanation": "Missense variants are amenable to pyridoxine treatment",
    "difficulty_rationale": "",
    "sources": ["GeneReviews"],
    "citations": ["https://www.ncbi.nlm.nih.gov/books/NBK1283/"]
  },
  {
    "id": "AITX-00005",
    "patient": {
      "genotype": [
        {
          "gene": "AGXT",
          "transcript": "NM_000030.3",
          "variant_cdna": "c.33dup",
          "variant_protein": "p.(Lys12GlnfsTer156)",
          "zygosity": "homozygous"
        }
      ],
      "clinical_context": "Recurrent nephrocalcinosis and chronic kidney disease"
    },
    "question": {
      "category": "Established_Targeted",
      "answer_format": "binary",
      "prompt": "Is this patient predicted to be responsive to pyridoxine? Answer yes or no.",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "No",
    "answer_explanation": "Pyridoxine is not effective for patients with null variants",
    "difficulty_rationale": "",
    "sources": ["GeneReviews"],
    "citations": ["https://www.ncbi.nlm.nih.gov/books/NBK1283/"]
  },
  {
    "id": "AITX-00006",
    "patient": {
      "genotype": [
        {
          "gene": "AGXT",
          "transcript": "NM_000030.3",
          "variant_cdna": "c.33dup",
          "variant_protein": "p.(Lys12GlnfsTer156)",
          "zygosity": "homozygous"
        }
      ],
      "clinical_context": "7 year old with recurrent nephrocalcinosis and chronic kidney disease"
    },
    "question": {
      "category": "Established_Targeted",
      "answer_format": "string_match",
      "prompt": "What targeted, genetic therapies are approved for this patient in the US? Provide the generic name.",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "Lumasiran",
    "answer_explanation": "Lumasiran is approved for patients of all ages whereas Nedosiran is only approved for patients age >9.",
    "difficulty_rationale": "slight change in patient age changes the answer",
    "sources": ["GeneReviews"],
    "citations": ["https://www.ncbi.nlm.nih.gov/books/NBK1283/"]
  },
  {
    "id": "AITX-00007",
    "patient": {
      "genotype": [
        {
          "gene": "DDC",
          "transcript": "NM_001082971.2",
          "variant_cdna": "c.286G>A",
          "variant_protein": "p.(Gly96Arg)",
          "zygosity": "homozygous"
        }
      ],
      "clinical_context": "Global developmental delay"
    },
    "question": {
      "category": "Established_Targeted",
      "answer_format": "string_match",
      "prompt": "What is the youngest age for which a gene therapy is approved for this patient's genetic condition in the united kingdom? Answer with the format \"X months\".",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "18 months",
    "answer_explanation": "specified on GeneReviews",
    "difficulty_rationale": "",
    "sources": ["GeneReviews"],
    "citations": ["https://www.ncbi.nlm.nih.gov/books/NBK595821/"]
  },
  {
    "id": "AITX-00008",
    "patient": {
      "genotype": [
        {
          "gene": "COL1A1",
          "transcript": "NM_000088.4",
          "variant_cdna": "c.1678G>A",
          "variant_protein": "p.(Gly560Ser)",
          "zygosity": "heterozygous"
        }
      ],
      "clinical_context": "joint hypermobility, skin hyperextensibility, and easy bruising"
    },
    "question": {
      "category": "Established_Supportive",
      "answer_format": "string_match",
      "prompt": "What two medications are most established for decreasing bruising? List generic names in alphabetical order",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "ascorbic acid, desmopressin",
    "answer_explanation": "specified in management on GeneReviews",
    "difficulty_rationale": "",
    "sources": ["GeneReviews"],
    "citations": ["https://www.ncbi.nlm.nih.gov/books/NBK1244/#eds.Management"]
  },
  {
    "id": "AITX-00009",
    "patient": {
      "genotype": [
        {
          "gene": "SLC35A2",
          "transcript": "NM_005660.3",
          "variant_cdna": "c.3G>A",
          "variant_protein": "p.Met1Ile",
          "zygosity": "heterozygous"
        }
      ],
      "clinical_context": "Patient with SLC35A2-CDG who is experiencing seizures and global developmental delay"
    },
    "question": {
      "category": "Clinical_Trials",
      "answer_format": "string_match",
      "prompt": "What clinical trial developing a new therapeutic for this condition is recruiting or listed as upcoming/not yet recruiting? Return a clinical trials ID",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "NCT05402384",
    "answer_explanation": "search for SLC35A2 on ClinicalTrials.gov returns only 2 trials, 1 of which is upcoming",
    "difficulty_rationale": "",
    "sources": ["ClinicalTrials.gov"],
    "citations": ["https://clinicaltrials.gov/study/NCT05402384"]
  },
  {
    "id": "AITX-00010",
    "patient": {
      "genotype": [
        {
          "gene": "SLC35A2",
          "transcript": "NM_005660.3",
          "variant_cdna": "c.3G>A",
          "variant_protein": "p.Met1Ile",
          "zygosity": "heterozygous"
        }
      ],
      "clinical_context": "seizures and global developmental delay. Age 2 months, Hemoglobin 5, Normal liver labs, Not enrolled in other trials"
    },
    "question": {
      "category": "Clinical_Trials",
      "answer_format": "binary",
      "prompt": "Is this patient eligible for clinical trial NCT05402384? Answer yes or no.",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "No",
    "answer_explanation": "Exclusion criteria lists hemoglobin <7",
    "difficulty_rationale": "",
    "sources": ["ClinicalTrials.gov"],
    "citations": ["https://clinicaltrials.gov/study/NCT05402384"]
  },
  {
    "id": "AITX-00011",
    "patient": {
      "genotype": [
        {
          "gene": "KCNT1",
          "transcript": "NM_020822.3",
          "variant_cdna": "c.2849G>A",
          "variant_protein": "p.Arg950Gln",
          "zygosity": "heterozygous"
        }
      ],
      "clinical_context": "early-onset seizures and developmental delays"
    },
    "question": {
      "category": "Clinical_Trials",
      "answer_format": "string_match",
      "prompt": "For which clinical trials evaluating new therapeutics is this patient eligible? Provide a clinical trial ID or answer None.",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "None",
    "answer_explanation": "Only a natural history study is listed.",
    "difficulty_rationale": "",
    "sources": ["ClinicalTrials.gov"],
    "citations": ["https://clinicaltrials.gov/search?cond=KCNT1"]
  },
  {
    "id": "AITX-00012",
    "patient": {
      "genotype": [
        {
          "gene": "GRIN2B",
          "transcript": "NM_000834.5",
          "variant_cdna": "c.2755C>T",
          "variant_protein": "p.Gln919Ter",
          "zygosity": "heterozygous"
        }
      ],
      "clinical_context": "intellectual disability, seizures, and developmental delays"
    },
    "question": {
      "category": "Drug_Development_and_Repurposing",
      "answer_format": "multiple_choice",
      "prompt": "Is it more likely amenable to treatment with Memantine, L-serine, or Radiprodil",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "L-Serine",
    "answer_explanation": "Variant is a LOF variant. L-serine is being used for LOF variants whereas the others are being used for GOF variants",
    "difficulty_rationale": "",
    "sources": ["PubMed/Literature"],
    "citations": ["https://academic.oup.com/brain/article/147/5/1653/7611854?login=false"]
  },
  {
    "id": "AITX-00013",
    "patient": {
      "genotype": [
        {
          "gene": "ANO10",
          "transcript": "NM_018075.5",
          "variant_cdna": "c.289del",
          "variant_protein": "p.(Met97Ter)",
          "zygosity": "homozygous"
        }
      ],
      "clinical_context": "progressive cerebellar ataxia and peripheral neuropathy"
    },
    "question": {
      "category": "Variant_Assessment",
      "answer_format": "numeric_match",
      "prompt": "How many amino acids are coded for by the exon in which this variant occurs? Answer with a number",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "66",
    "answer_explanation": "visual inspection on Ensembl",
    "difficulty_rationale": "",
    "sources": ["Other"],
    "otherSource": "Ensembl",
    "citations": []
  },
  {
    "id": "AITX-00014",
    "patient": {
      "genotype": [
        {
          "gene": "ANO10",
          "transcript": "NM_018075.5",
          "variant_cdna": "c.289del",
          "variant_protein": "p.(Met97Ter)",
          "zygosity": "homozygous"
        }
      ],
      "clinical_context": "progressive cerebellar ataxia and peripheral neuropathy"
    },
    "question": {
      "category": "Variant_Assessment",
      "answer_format": "numeric_match",
      "prompt": "What percentage of the total coding transcript for this gene are encoded by the exon in which this variant occurs? Answer with a decimal to nearest tenth.",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "0.1",
    "answer_explanation": "66/660 = 0.1",
    "difficulty_rationale": "",
    "sources": ["Other"],
    "otherSource": "Ensembl",
    "citations": []
  },
  {
    "id": "AITX-00015",
    "patient": {
      "genotype": [
        {
          "gene": "KMT2B",
          "transcript": "NM_014727.3",
          "variant_cdna": "c.8079delC",
          "variant_protein": "p.(Ile2694SerfsTer44)",
          "zygosity": "heterozygous"
        }
      ],
      "clinical_context": "childhood-onset generalized dystonia"
    },
    "question": {
      "category": "Variant_Assessment",
      "answer_format": "binary",
      "prompt": "Based on typical prediction rules, is this variant likely to result in nonsense mediated decay? Answer yes or no.",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "No",
    "answer_explanation": "At the end of the last exon, after the main domain",
    "difficulty_rationale": "",
    "sources": ["Other"],
    "otherSource": "Ensembl",
    "citations": []
  },
  {
    "id": "AITX-00016",
    "patient": {
      "genotype": [
        {
          "gene": "NF1",
          "transcript": "NM_001042492.3",
          "variant_cdna": "c.3728T>C",
          "variant_protein": "p.(Leu1243Pro)",
          "zygosity": "heterozygous"
        }
      ],
      "clinical_context": "Malignant Peripheral Nerve Sheath Tumor and Pheochromocytoma"
    },
    "question": {
      "category": "Variant_Assessment",
      "answer_format": "multiple_choice",
      "prompt": "In which functional domain does this variant occur? Answer choices: CSRD, TBD, GRD, Sec14-PH, HLR, NLS, SBR.",
      "date_submitted": "2025-08-01"
    },
    "answer_expected": "GRD",
    "answer_explanation": "GRD, GAP related domain (1198–1549 residues)",
    "difficulty_rationale": "",
    "sources": ["PubMed/Literature"],
    "citations": ["https://www.mdpi.com/2073-4425/13/7/1130#"]
  }
]